HC Wainwright Reiterates Buy Rating for Astria Therapeutics (NASDAQ:ATXS)

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a $16.00 target price on the biotechnology company’s stock.

Separately, Oppenheimer boosted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Stock Performance

Shares of ATXS stock opened at $7.55 on Thursday. Astria Therapeutics has a 1 year low of $7.16 and a 1 year high of $16.90. The business’s fifty day moving average is $9.16 and its 200-day moving average is $10.58. The stock has a market cap of $426.05 million, a PE ratio of -3.61 and a beta of 0.70.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds have recently modified their holdings of ATXS. Quest Partners LLC boosted its position in shares of Astria Therapeutics by 180.8% in the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares during the period. SG Americas Securities LLC lifted its stake in Astria Therapeutics by 51.3% during the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 7,218 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after buying an additional 11,763 shares during the period. PDT Partners LLC purchased a new position in shares of Astria Therapeutics in the third quarter worth approximately $140,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Astria Therapeutics during the second quarter valued at approximately $171,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.